- Home
- EM vs TLSI Comparison
EM vs TLSI Comparison
Compare EM & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EM | TLSI |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.5M | 244.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EM | TLSI |
|---|---|---|
| Price | $1.34 | $7.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.25 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 715.7K | 175.5K |
| Earning Date | 11-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $259,541,587.00 | $40,207,000.00 |
| Revenue This Year | $3.30 | $55.06 |
| Revenue Next Year | $5.26 | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $0.68 | $3.42 |
| 52 Week High | $1.46 | $7.70 |
Technical Indicators
Market Signals| Indicator | EM | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 68.63 |
| Support Level | $1.33 | $6.06 |
| Resistance Level | $1.40 | $7.70 |
| Average True Range (ATR) | 0.04 | 0.58 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 14.29 | 80.42 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.